do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline Comparison of and do not combine dpp-4 inhibitors

At 10mg/ml, you are drawing 75 units, which is manageable but getting close to the upper end

150 Although metabolic adjustments based on GLP-1RA, such as improvements in insulin resistance, do not provide additional benefits beyond direct antiviral therapy for HCV, 142 the direct antiviral benefits of GLP-1RA against HCV remain in question

Sleep apnea improvement: ZepBound is now FDA-approved for sleep apnea in people with obesity, as weight loss can ease symptoms like snoring and disrupted breathing

The expression and distribution of FFARs such as GPR40, GPR119, and GPR120 in L and cells and glucose, along with their dual effects on insulin and GLP-1 secretion, have made them attractive therapeutic targets, leading to the development of agonists for these receptors for the treatment of T2DM [150,151,152,153,154]

doi:10.1038/labinvest.2014.50 109